Scarica l'app Stockscreener
1.22
17.31%
0.18
Dopo l'orario di chiusura:
1.15
-0.07
-5.74%
Precedente Chiudi:
$1.04
Aprire:
$1.04
Volume 24 ore:
220.38K
Relative Volume:
15.03
Capitalizzazione di mercato:
$4.02M
Reddito:
-
Utile/perdita netta:
$-9.60M
Rapporto P/E:
-0.3675
EPS:
-3.32
Flusso di cassa netto:
$-8.96M
1 W Prestazione:
-1.37%
1M Prestazione:
+6.09%
6M Prestazione:
-14.08%
1 anno Prestazione:
+3.39%
Intervallo 1D:
$1.04
$1.32
Intervallo di 1 settimana:
$1.02
$1.32
Portata 52W:
$1.00
$1.75
Artelo Biosciences Inc Stock (ARTL) Company Profile
Nome
Artelo Biosciences Inc
Settore
Industria
Telefono
858-925-7049
Indirizzo
505 LOMAS SANTA FE, SUITE 160, SOLANA BEACH, CA
Confronta ARTL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| ARTL | 1.22 | 4.02M | 0 | -9.60M | -8.96M | -3.32 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Artelo Biosciences Inc Stock (ARTL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-02-12 | Iniziato | Ladenburg Thalmann | Buy |
Artelo Biosciences Inc Borsa (ARTL) Ultime notizie
Artelo Biosciences to Present Key Drug Development Data at Major Cannabinoid Summit | ARTL Stock News - StockTitan
HC Wainwright Has Negative Outlook of ARTL FY2024 Earnings - Defense World
HC Wainwright Reiterates “Buy” Rating for Artelo Biosciences (NASDAQ:ARTL) - Defense World
Cancer Anorexia Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Helsinn Healthcare, Artelo Biosciences, NGM Biopharmaceuticals - The Globe and Mail
Artelo Biosciences Reports Q3 2024 Financials and Progress - TipRanks
Artelo Biosciences (ARTL) Stock Dips Amidst Financial Report - GuruFocus.com
Artelo Biosciences Announces Promising New Data on Novel Non-Opioid Treatment Approach for Osteoarthritis Pain at the 13th Annual Musculoskeletal Repair and Regeneration Symposium - The Manila Times
Artelo's Pain Drug Outperforms Naproxen in Key Study; FDA Clears Phase 1 Trial | ARTL Stock News - StockTitan
Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma - The Manila Times
Artelo Bio Slashes Losses 54%, Advances Pipeline with Multiple Clinical Trials Ahead | ARTL Stock News - StockTitan
Artelo Biosciences Inc. (ARTL) Quarterly 10-Q Report - Quartzy
Artelo Biosciences (ARTL) Shares Dive Amidst Biotech Sector Move - GuruFocus.com
Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer's Annual Meeting - The Manila Times
Artelo Biosciences Announces Acceptance of ART26.12 into the National Institutes of Health’s “Preclinical Screening Platform for Pain” Program - StockTitan
Artelo Biosciences (ARTL) Stock Surges Amid Bullish Analyst Rati - GuruFocus.com
Artelo Biosciences CEO to Participate in Fireside Chat at the Maxim Group Virtual Healthcare Summit on October 16th - The Manila Times
How doctors hope new cannabis drug will help cancer patients gain weight - inews
FABP5 inhibitor ART-26.12 exhibits activity in psoriasis models - BioWorld Online
Artelo Biosciences shares initiated with Buy by EF Hutton - Investing.com UK
EF Hutton Initiates Coverage of Artelo Biosciences (ARTL) with Buy Recommendation - MSN
Equities Analysts Offer Predictions for Stitch Fix, Inc.’s Q1 2025 Earnings (NASDAQ:SFIX) - Defense World
Artelo Biosciences, Inc. (NASDAQ:ARTL) Short Interest Update - Defense World
Anorexia Nervosa Market Expected to Experience Major Growth - openPR
ARTL stock touches 52-week low at $1.12 amid market challenges - Investing.com Canada
Artelo Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference - ForexTV.com
ARTL Stock Earnings: Artelo Biosciences Beats EPS for Q2 2024 - MSN
ARTLW (Artelo Biosciences) EV-to-Revenue : (As of Aug. 18, 2024) - GuruFocus.com
ARTL (Artelo Biosciences) EV-to-Revenue : (As of Aug. 18, 2024) - GuruFocus.com
ARTL (Artelo Biosciences) EV-to-Revenue : (As of Aug. 17, 2024) - GuruFocus.com
HC Wainwright Weighs in on Artelo Biosciences, Inc.’s Q3 2024 Earnings (NASDAQ:ARTL) - Defense World
Artelo Biosciences’ (ARTL) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Artelo Biosciences (NASDAQ:ARTL) Announces Earnings Results - Defense World
Artelo Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update - BioSpace
Artelo Biosciences, Inc. (NASDAQ:ARTL) Short Interest Up 3,808.3% in July - Defense World
Artelo Biosciences, Inc. (NASDAQ:ARTL) Short Interest Down 91.5% in July - Defense World
New drug to control pain related to cancer treatment originally developed at Stony Brook gets FDA clearance - TBR News Media
UK life sciences can lead the way in global cannabinoid R&D says CRDG report - European Pharmaceutical Manufacturer
Artelo’s FABP5 inhibitor cleared to enter clinic for chemotherapy-induced peripheral neuropathy - BioWorld Online
Artelo Biosciences Inc (ARTL)’s Market Momentum: Closing Strong at 1.33, Up 2.71 - The Dwinnex
FDA greenlights Artelo Biosciences' neuropathy drug trial By Investing.com - Investing.com Nigeria
PSEG sets $0.60 quarterly dividend for Q3 2024 By Investing.com - Investing.com
Artelo Biosciences Inc (ARTL) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
FDA clears Artelo’s FABP5 inhibitor trial - Yahoo Finance
Artelo stock jumps 13% after FDA okays ART26.12 Phase 1 study (NASDAQ:ARTL) - Seeking Alpha
Artelo Biosciences Receives FDA Clearance of its IND Application for ART26.12, a Selective Fatty Acid Binding Protein 5 Inhibitor - ForexTV.com
Pharmacokinetic evaluation of novel cannabidiol formulation presented - BioWorld Online
Artelo Biosciences Presents Data From Preclinical Studies On ART12.11 At 34th Annual International Cannabinoid Research Society Symposium - Quantisnow
Artelo Biosciences Presents Comparative Data from Key Preclinical Studies on ART12.11 at the 34th Annual International Cannabinoid Research Society Symposium - Yahoo Finance
Artelo Biosciences Announces Data Supporting Broad Potential Utility of its FABP Inhibitor Platform - StockTitan
Artelo Biosciences Presents Preclinical Data on ART26.12 in Breast Cancer-Induced Bone Pain at the 34th Annual International Cannabinoid Research Society Symposium - Quantisnow
Q4 Investor Summit Small Cap & Micro Cap Conference To Offer Opportunity to Meet with C-level Management of 90 ... - The Globe and Mail
Artelo Biosciences Inc Azioni (ARTL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.66%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):